About 10% of the population carries certain genetic variants linked to a newly identified phenomenon called GLP-1 resistance
GLP-1 receptor agonists are medications originally developed for type 2 diabetes that mimic a natural gut hormone involved in appetite, blood sugar regulation and digestion
Genetic variants in the GLP1R gene, FTO, MC4R, and GIPR may influence appetite regulation, weight loss trajectory, and side effect susceptibility
GLP-1 is an incretin hormone released in response to postprandial glucose, which promotes increased insulin secretion
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al
Add water to the vial wall, not the powder